Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.
Polack, FP; Thomas, SJ; Kitchin, N; Absalon, J; Gurtman, A; Lockhart, S; Perez, JL; Marc, GP; Moreira, ED; Zerbini, C; et al.
The New England journal of medicine.
2020;
383:2603-2615.
Safety and immunogenicity of two RNA-based covid-19 vaccine candidates.
Walsh, EE; Frenck, RW; Falsey, AR; Kitchin, N; Absalon, J; Gurtman, A; Lockhart, S; Neuzil, K; Mulligan, MJ; Bailey, R; et al.
The New England journal of medicine.
2020;
383:2439-2450.
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.
Mulligan, MJ; Lyke, KE; Kitchin, N; Absalon, J; Gurtman, A; Lockhart, S; Neuzil, K; Raabe, V; Bailey, R; Swanson, KA; et al.
Nature.
2020;
586:589-593.
Immune response characterization after controlled infection with lyophilized shigella sonnei 53G.
Clarkson, KA; Frenck, RW; Dickey, M; Suvarnapunya, AE; Chandrasekaran, L; Weerts, HP; Heaney, CD; McNeal, M; Detizio, K; Parker, S; et al.
mSphere.
2020;
5.
Establishment of a controlled human infection model with a lyophilized strain of shigella sonnei 53G.
Frenck, RW; Dickey, M; Suvarnapunya, AE; Chandrasekaran, L; Kaminski, RW; Clarkson, KA; McNeal, M; Lynen, A; Parker, S; Hoeper, A; et al.
mSphere.
2020;
5.
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study.
Walsh, EE; Frenck, R; Falsey, AR; Kitchin, N; Absalon, J; Gurtman, A; Lockhart, S; Neuzil, K; Mulligan, MJ; Bailey, R; et al.
2020.
Hospital-acquired pneumonia and ventilator-associated pneumonia in children: A prospective natural history and case-control study.
Ericson, JE; McGuire, J; Michaels, MG; Schwarz, A; Frenck, R; Deville, JG; Agarwal, S; Bressler, AM; Gao, J; Spears, T; et al.
The Pediatric Infectious Disease Journal.
2020;
39:658-664.
Hospital-acquired Pneumonia and Ventilator-associated Pneumonia in Children.
Ericson, JE; McGuire, J; Michaels, MG; Schwarz, A; Frenck, R; Deville, JG; Agarwal, S; Bressler, AM; Gao, J; Spears, T; et al.
The Pediatric Infectious Disease Journal.
2020;
39:658-664.
Third human challenge trial conference, Oxford, United Kingdom, February 6–7, 2020, a meeting report.
Pollard, AJ; Sauerwein, R; Baay, M; Neels, P; Balasingam, S; Bejon, P; Berthels, N; Bull, S; Catchpole, A; Chi, P; et al.
(2020)
Elsevier BV.
66:41-52.
Persistence of immune responses through 36 months in healthy adults after vaccination with a novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag).
Creech, CB; Frenck, RW; Fiquet, A; Feldman, R; Kankam, MK; Pathirana, S; Baber, J; Radley, D; Cooper, D; Eiden, J; et al.
Open Forum Infectious Diseases.
2020;
7.